ChemicalBook > CAS DataBase List > MLN0905

MLN0905

MLN0905 Structure
MLN0905
  • CAS No.1228960-69-7
  • Chemical Name:MLN0905
  • CBNumber:CB72628151
  • Molecular Formula:C24H25F3N6S
  • Formula Weight:486.56
  • MOL File:1228960-69-7.mol
MLN0905 Property
  • Boiling point 624.4±65.0 °C(Predicted)
  • Density 1.37±0.1 g/cm3 (20 ºC 760 Torr)
  • storage temp. Store at -20°C
  • solubility ≥24.35 mg/mL in DMSO
  • pka 9.80±0.20(Predicted)
  • form solid
  • color Off-white to yellow
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H315-H319-H335
  • Precautionary statements P261-P305+P351+P338

MLN0905 Chemical Properties,Usage,Production

  • Uses MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer[1][2].
  • Biological Activity mln0905 is a potent inhibitor of plk1 with ic50 value ranges from 3 to 24 nm [1].polo-like kinase 1 (plk1) is a family of conserved serine/threonine kinases and plays an important role in regulating cell cycle. it has been revealed that plk1 drives cell cycle progression by triggerting g2/m transition and is considered as a pro-oncogene which overexpressed in tumor cells [2].mln0905 is a selective plk1 inhibitor and has similar effect as rnai hnockdown. when tested with ht-29 cells, mln0905 treatment significantly increased phish3 expression which indicated that cells were arrested in g2/m phase by inhibiting plk1 expression [1].in mouse model with human diffuse large b-cell lymphoma (dlbcl) cell line ocily-19 subcutaneous xenograft, co-administration of mln0905 and rituximab markedly reduced tumor volume and increased survival time through inhibiting plk1 which resulted in mitotic arrest [1]. and the same result was achieved when using nude mice model with human colon tumor ht29 xenograft, mln0905 treatment significantly inhibited tumor growth or progression [3].
  • in vivo

    MLN0905 (p.o.; 50 mg/kg) shows a high sustained PD response in nude mice HT29 xenograft tumors[1].
    MLN0905 (p.o.; 6.25, 12.5, 25, 50 mg/kg) exhibits significant antitumor activities in mice HT29 xenograft tumors[1].
    MLN0905 (p.o.; 0-14.5 mg/kg; daily, QD×3/week) has marked antitumor effects in kinds of lymphoma xenograft model[1][2].

    Animal Model:Tumor (HT29) xenograft model[1]
    Dosage:0-50 mg/kg
    Administration:P.O; daily, QD×3/week
    Result:Observed antitumor activity, tumor stasis or regression and well-tolerated oral doses.
  • target PLK1
  • IC 50 PLK1: 2 nM (IC50)
  • References [1]. shi, j.q., et al., mln0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large b-cell lymphoma. mol cancer ther, 2012. 11(9): p. 2045-53.
    [2]. espeut, j., et al., natural loss of mps1 kinase in nematodes uncovers a role for polo-like kinase 1 in spindle checkpoint initiation. cell rep, 2015.
    [3]. duffey, m.o., et al., discovery of a potent and orally bioavailable benzolactam-derived inhibitor of polo-like kinase 1 (mln0905). j med chem, 2012. 55(1): p. 197-208.
MLN0905 Preparation Products And Raw materials
Raw materials
Preparation Products
MLN0905 Suppliers
Global(93)Suppliers
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32202
  • Advantage：58
  • Supplier：
    Shanghai UCHEM Inc.
  • Tel：+862156762820<br/>+86-13564624040
  • Email：sales@myuchem.com
  • Country：China
  • ProdList：7906
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
  • Supplier：
    Aceschem Inc.
  • Tel：+1-817863-6948<br/>+1-（817）863-6948
  • Email：sales@aceschem.com
  • Country：United States
  • ProdList：19632
  • Advantage：58
MLN0905 Spectrum
1228960-69-7, MLN0905Related Search:
  • API
  • Inhibitors
  • 生物试剂
  • 抑制剂
  • 合成有机化合物配体
  • 细胞生物学试剂
  • 小分子抑制剂
  • 小分子抑制剂，天然产物
  • 细胞周期
  • C24H25F3N6S
  • 化合物MLN0905,10 MM DMSO 溶液
  • 2-((5-(3-(二甲基氨基)丙基)-2-甲基吡啶-3-基)氨基)-9-(三氟甲基)-5,7-二氢-6H-苯并[B]嘧啶并[4,5-D]氮杂卓-6-硫酮
  • PLK1抑制剂(MLN0905)
  • 2-[[5-[3-(二甲基氨基)丙基]-2-甲基-3-吡啶基]氨基]-5,7-二氢-9-(三氟甲基)- 6H-嘧啶并[5,4-D][1]苯并氮杂卓-6-硫酮
  • 1228960-69-7
  • MLN0905, 10 mM in DMSO
  • 2-((5-(3-(Dimethylamino)propyl)-2-methylpyridin-3-yl)amino)-9-(trifluoromethyl)-5,7-dihydro-6H-benzo[b]pyrimido[4,5-d]azepine-6-thione
  • AI3-14412
  • AI314412
  • AI3 14412
  • MLN0905 USP/EP/BP
  • PLK1 INHIBITOR; MLN 0905; MLN-0905
  • CS-1458
  • PLK1 Inhibitor
  • MLN0905 2-[[5-[3-(Dimethylamino)propyl]-2-methyl-3-pyridinyl]amino]-5,7-dihydro-9-(trifluoromethyl)- 6H-pyrimido[5,4-d][1]benzazepine-6-thione
  • 2-[[5-[3-(Dimethylamino)propyl]-2-methyl-3-pyridinyl]amino]-5,7-dihydro-9-(trifluoromethyl)- 6H-pyrimido[5,4-d][1]benzazepine-6-thione MLN0905
  • 6H-Pyrimido[5,4-d][1]benzazepine-6-thione, 2-[[5-[3-(dimethylamino)propyl]-2-methyl-3-pyridinyl]amino]-5,7-dihydro-9-(trifluoromethyl)-
  • 2-[[5-[3-(Dimethylamino)propyl]-2-methyl-3-pyridinyl]amino]-5,7-dihydro-9-(trifluoromethyl)- 6H-pyrimido[5,4-d][1]benzazepine-6-thione
  • MLN0905

Home

My